# Acantholytic Dermatosis of the Vulvocrural Area

Ravi S. Krishnan, Houston, Texas Leslie S. Ledbetter, MD, Houston, Texas Jon A. Reed, MD, Houston, Texas Sylvia Hsu, MD, Houston, Texas

#### GOAL

To discuss a case of acantholytic dermatosis of the vulvocrural area

#### **OBJECTIVES**

Upon completion of this activity, dermatologists and general practitioners should be able to:

- 1. Describe the clinical presentation of acantholytic dermatosis of the vulvocrural area.
- 2. Outline etiological possibilities and the differential diagnosis of acantholytic dermatosis.
- 3. Delineate treatment for acantholytic dermatosis.

CME Test on page 220.

This article has been peer reviewed and approved by Michael Fisher, MD, Professor of Medicine, Albert Einstein College of Medicine. Review date: February 2001.

This activity has been planned and implemented in accordance with the Essentials and Standards of the Accreditation Council for Continuing Medical Education through the joint sponsorship of Albert Einstein College of Medicine and Quadrant HealthCom, Inc. The Albert Einstein College of Medicine is accredited by the

ACCME to provide continuing medical education for physicians.

Albert Einstein College of Medicine designates this educational activity for a maximum of 1.0 hour in category 1 credit toward the AMA Physician's Recognition Award. Each physician should claim only those hours of credit that he/she actually spent in the educational activity.

This activity has been planned and produced in accordance with ACCME Essentials

Acantholytic dermatosis of the vulvocrural area is a rare skin disorder characterized by solitary or multiple skin-colored to white, smooth papules or plaques. Histopathological features of both Hailey-Hailey disease and Darier's disease are present. There is acantholysis, which may involve the full thickness of the epidermis, and dyskeratosis with corps ronds and grains. There may be marked hy-

perkeratosis and focal parakeratosis. We report a case of this rare disease and discuss its differential diagnosis and treatment.

cantholytic dermatosis of the vulvocrural area is an uncommon clinical and histopathological entity that belongs to the spectrum of focal acantholytic dyskeratoses described by Ackerman. In 1984, Chorzelski et al² proposed the term papular acantholytic dyskeratosis of the vulva to describe the disorder and suggested that this dermatosis may represent a unique entity. Since the initial description by Chorzelski et al, there have been sporadic reports of acantholytic dermatoses of the vulvocrural area, 3-7 as well as a report of clinically and histologically similar lesions in males.8

Mr. Krishnan and Drs. Ledbetter, Reed, and Hsu are from Baylor College of Medicine, Houston, Texas. Mr. Krishnan is a medical student. Dr. Ledbetter is a Resident in the Department of Dermatology. Dr. Reed is Associate Professor in the Departments of Pathology and Dermatology. Dr. Hsu is Associate Professor in the Department of Dermatology.

Reprints: Sylvia Hsu, MD, Department of Dermatology, Baylor College of Medicine, One Baylor Plaza, Houston, TX 77030.



**Figure 1.** Confluent skin-colored papules on the medial thighs, inguinal folds, and labia majora.

# **Case Report**


A 27-year-old Hispanic woman presented with a 9-month history of a slightly pruritic eruption in her groin. There was no family history of similar lesions. On physical examination, the patient showed confluent skin-colored, smooth, 2- to 4-mm papules on her medial thighs, inguinal folds, and labia majora that coalesced into plaques (Figure 1).

A 4-mm punch biopsy revealed acantholysis involving the suprabasal layers of the epidermis and dyskeratosis with some cells resembling corps ronds and grains (Figure 2). Direct immunofluorescence was negative, and treatment with topical tretinoin 0.05% cream produced no significant improvement.

# Comment

Acantholytic dermatosis of the vulvocrural area presents as solitary or multiple skin-colored to white, smooth papules or plaques. The lesions are most commonly located on the labia majora but also may be located elsewhere in the perineum, in the inguinal folds, or on the superior medial aspects of the thighs. Two cases have been reported in which the submammary region also was involved. The papules may be painful or pruritic. Concurrent Candida vaginitis was observed in a small minority of cases.

Acantholytic dermatosis of the vulvocrural area displays histological features of both Hailey-Hailey



**Figure 2.** Acantholysis involving the suprabasal layers of the epidermis and dyskeratosis with some cells resembling corps ronds and grains (H&E, original magnification ×250).

disease and Darier's disease. There is prominent acantholysis, which may involve the full thickness of the epidermis, and dyskeratosis with corps ronds and grains.<sup>5</sup> There may be pronounced hyperkeratosis and focal parakeratosis.<sup>4,6</sup> Direct immunofluorescence studies are consistently negative, with no deposition of immunoglobulin or complement in the skin.<sup>2,6</sup> Indirect immunofluorescence studies are also negative.<sup>2,3,6</sup>

The differential diagnosis of acantholytic dermatosis of the vulvocrural area consists of acantholytic disorders that can produce lesions localized to the genital region, 7,9-11 including Darier's disease, Hailey-Hailey disease, pemphigus vegetans, warty dyskeratoma, and squamous cell carcinoma. These disorders are usually distinguished from each other on the basis of clinical and histopathological features. When performing a diagnostic evaluation, it is crucial to establish a negative family history. This helps to distinguish acantholytic dermatosis of the vulvocrural area from Darier's disease and Hailey-Hailey disease, 9,10 which are autosomal dominant acantholytic disorders. Immunofluorescence studies also are significant because negative results will rule out pemphigus vegetans.7

Grover's disease (transient acantholytic dermatosis) also produces histologically similar lesions. However, it is excluded from the differential diagnosis because, unlike acantholytic dermatosis of the vulvocrural area, it consistently involves the trunk and often resolves within weeks to months.<sup>12</sup>

The etiology and pathogenesis of acantholytic dermatosis of the vulvocrural area are not fully elucidated. Electron microscopy shows a disappearance

of intercellular connections and a reduced number of desmosomes.<sup>5</sup> In addition, there is detachment of tonofilaments from the desmosomal plate and perinuclear aggregations of tonofilaments.<sup>5</sup> The underlying cause of these changes is unknown. It has been hypothesized that the warm, moist environment of the genital region triggers this disorder and accounts for the localization of lesions to the vulvocrural area.<sup>4,8</sup> Furthermore, Coppola et al<sup>3</sup> suggest a possible connection between ovarian hormones and the pathogenesis of this disease, based on their patient's premenstrual exacerbations of itching and burning.

Effective treatment of acantholytic dermatosis of the vulvocrural area is difficult. The lesions tend to persist for years. With the exception of topical tretinoin cream, which has been reported to give only a transient improvement in a single patient, there is no evidence that any topical or systemic medication can ameliorate or cure this dermatosis. Chorzelski et al<sup>2</sup> described the failure of corticosteroids (local and systemic) and sulfones to improve the eruption. Coppola et al<sup>3</sup> also reported the failure of multiple treatments.

Surgical treatments, although impractical for multiple lesions, have proven more effective than medications. Cooper<sup>4</sup> reports that excision of localized lesions is curative, based on follow-up periods ranging from 3 to 30 months. Furthermore, some papules have been successfully removed by electrocautery.<sup>2</sup>

## REFERENCES

- Ackerman AB. Focal acantholytic dyskeratosis. Arch Dermatol. 1972;106:702-706.
- 2. Chorzelski TP, Kudejko J, Jablonska S. Is papular acantholytic dyskeratosis of the vulva a new entity? *Am J Dermatopathol*. 1984;6:557-560.
- 3. Coppola G, Muscardin LM, Piazza P. Papular acantholytic dyskeratosis [letter]. *Am J Dermatopathol*. 1986;8:364-365.
- 4. Cooper PH. Acantholytic dermatosis localized to the vulvocrural area. *J Cutan Pathol*. 1989;16:81-84.
- Van Joost T, Vuzevski VD, Tank B, et al. Benign persistent papular acantholytic and dyskeratotic eruption: a case report and review of the literature. Br J Dermatol. 1991;124:92-95.
- 6. Leverkus M, Rose C, Brocker EB, et al. Intertrigenous acantholytic dermatosis: abortive form of Darier's disease or a specific entity? *Hautzart*. 1999;50:733-738.
- 7. Wong KT, Wong KK. A case of acantholytic dermatosis of the vulva with features of pemphigus vegetans. *J Cutan Pathol*. 1994;21:453-456.
- 8. Wong TY, Mihm MC Jr. Acantholytic dermatosis localized to genitalia and crural areas of male patients: a report of three cases. *J Cutan Pathol*. 1994;21:27-32.
- 9. Wieselthier JS, Pincus SH. Hailey-Hailey disease of the vulva [letter]. *Arch Dermatol*. 1993;129:1344-1345.
- Salopek TG, Krol A, Jimbow K. Case report of Darier disease localized to the vulva in a 5-year-old girl. *Pediatr Dermatol.* 1993;10:146-148.
- 11. Duray PH, Merino MJ, Axiotis C. Warty dyskeratoma of the vulva. *Int J Gynecol Pathol*. 1983;2:286-293.
- 12. Heenan PJ, Quirk CJ. Transient acantholytic dermatosis. Br J Dermatol. 1980;102:515-520.

### **DISCLAIMER**

The opinions expressed herein are those of the authors and do not necessarily represent the views of the sponsor or its publisher. Please review complete prescribing information of specific drugs or combination of drugs, including indications, contraindications, warnings, and adverse effects before administering pharmacologic therapy to patients.

## **FACULTY DISCLOSURE**

The Faculty Disclosure Policy of the College of Medicine requires that faculty participating in a CME activity disclose to the audience any relationship with a pharmaceutical or equipment company that might pose a potential, apparent, or real conflict of interest with regard to their contribution to the program. It is required by the Accreditation Council for Continuing Medical Education that each author of a CME article disclose to the participants any discussion of an unlabeled use of a commercial product or device or an investigational use not yet approved by the Food and Drug Administration. Mr. Krishnan and Drs. Ledbetter, Reed, and Hsu report no conflict of interest. Dr. Fisher reports no conflict of interest.